Andere talen IGC Pharma, Inc.

Aandelen

IGC

US45408X3089

Beurs gesloten - Nyse Andere beurzen 22:00:00 21-05-2024			Nabeurs 00:30:16
0,5129 ^USD	-4,86%		0,512	-0,18%

16/04	IGC Pharma, Inc. kondigt aan dat tussentijdse gegevens van haar klinische fase 2-studie een klinisch significante afname, die de statistische significantie nadert, laten zien van agitatie bij Alzheimer in week twee vergeleken met placebo	CI
22/03	Aurora, Canopy onder Cannabisaandelen stijgen nadat Duitsland gedeeltelijke legalisatiewet aanneemt	MT

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

IGC Pharma to Attend BIO International Convention 2024	21/05
6.7 Million Americans Live With Alzheimerâ€™s â€“ IGC Pharma Believes They Deserve Treatment Options Without Black Box Warnings	09/05
IGC PHARMA : Announces Positive Interim Results for IGC-AD1 in Reducing Alzheimer’s Agitation	26/04
IGC-AD1'S Interim Phase 2 Data Show a Reduction in Alzheimer's Agitation at Week Two	17/04
IGC-AD1’s Interim Phase 2 Data Show a Reduction in Alzheimer’s Agitation at Week Two	16/04
IGC Pharma, Inc Announces Interim Data from Its Phase 2 Clinical Trial Demonstrates Clinically Significant Reduction, Approaching Statistical Significance, in Agitation in Alzheimer?S At Week Two Compared to Placebo	16/04
IGC Pharma Adds Advisor in Artificial Intelligence	09/04
IGC Pharma : Announces Positive Interim Results for IGC-AD1 in - Form 8-K	05/04
IGC Pharma Announces $3 Million Unregistered Private Placement of its Common Stock	26/03
Aurora, Canopy Among Cannabis Stocks Rising After Germany Passes Partial Legalization Law	22/03
Aurora Cannabis, Canopy Growth Among Cannabis Stocks Rising After Germany Passes Partial Legalization Law	22/03
IGC Pharma : Material Agreement - Form 8-K	22/03
IGC Pharma, Inc. announced that it expects to receive $3 million in funding from Bradbury Asset Management (Hong Kong) Limited	22/03
IGC Pharma Announces Positive Interim Results for IGC-AD1 in Reducing Alzheimer's Agitation	21/03
IGC Pharma Announces Positive Interim Results for IGC-AD1 in Reducing Alzheimer’s Agitation	20/03
IGC Pharma, Inc Announces the Results of an Interim Analysis of its Ongoing Phase 2 Trial Investigating IGC-Ad1 as Treatment for Agitation in Dementia from Alzheimer?s Disease	20/03
IGC PHARMA Announces its Participation at the Benzinga Virtual Healthcare Summit 2024	20/03
IGC Pharma (IGC): Healthcare Leader Terry Lierman Joins Board to Advance Alzheimer’s Pipeline	12/03
Igc Pharma, Inc. Appoints Terry Lierman as Independent Director to Its Board of Directors	12/03
Promising Results: TGR-63 Enhances Memory in Alzheimer's Mouse Model	28/02

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen IGC Pharma, Inc.

Aandelen

IGC

US45408X3089

Andere talen

Filters